icer white paper affordable access to glp-1 obesity medications 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 Today we're announcing the CMS

Steady nutrient release for consistent support

Weight loss drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) continue to have their moment in the medical space

For those of us in food science and product innovation, this is one of the most interesting shifts to watchone that may reshape not just individual categories but the entire landscape of packaged foods and foodservice offerings

The FDA has issued warnings about unapproved GLP-1 drugs circulating online - counterfeit, compounded, or mislabeled as research use only. When access to legitimate GLP-1 clinical trials is limited - by geography, logistics, or site capacity - progress slows

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimers disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs use...